Grifols S.A. (GRFS)
The price, the headline numbers and the latest news, in one place.
Grifols S.A. (GRFS) Stock Price, Analysis & Data
| Bid | 6.9 |
| Market Cap | 5.44B |
| Revenue (ttm) | 7.42B |
| Net Income (ttm) | 452M |
| 1.19 | |
| 0.77 | |
| 10.39 | |
| 5.61 | |
| P/B (ttm) | 1.68 |
| P/S (ttm) | 0.73 |
| Earnings Date | Feb 25, 2027 |
| Ask | 9.22 |
| Volume | 217,570 |
| Avg. Volume (20D) | 653,611 |
| Open | 8.03 |
| Previous Close | 7.99 |
| Day's Range | 7.98 - 8.12 |
| 52-Week Range | 6.96 - 10.23 |
| Analyst | n/a |
| Price Target | 10.87 (35.87%) |
| Dividends | $0.28 (3.52%) |
| Ex-Dividend Date | Jul 2, 2026 |
About GRFS
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurol...
Financial Performance
In 2025, Grifols S.A.'s revenue was 7.52B, an increase of 4.33% compared to the previous year's 7.21B. Earnings were 402M, an increase of 156.05%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for GRFS stock is "null". The 12-month stock price forecast is 10.87, which is upside of 35.87% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
